NTRA - Natera Inc Stock Price, Fair Value and News

$165.03-4.33 (-2.56%)

Delayed as of 22 Nov 2024, 11:28 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NTRA Price Action

Last 7 days

12.0%

Last 30 days

41.1%

Last 90 days

38.0%

Trailing 12 Months

209.8%

NTRA RSI Chart

NTRA Valuation

Market Cap

22.4B

Price/Earnings (Trailing)

-104.15

Price/Sales (Trailing)

14.6

EV/EBITDA

-126.41

Price/Free Cashflow

-673.77

NTRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NTRA Fundamentals

NTRA Revenue

Revenue (TTM)

1.5B

Rev. Growth (Yr)

63.9%

Rev. Growth (Qtr)

6.39%

NTRA Earnings

Earnings (TTM)

-214.7M

Earnings Growth (Yr)

71.02%

Earnings Growth (Qtr)

15.67%

NTRA Profitability

EBT Margin

-13.87%

Return on Equity

-24.44%

Return on Assets

-13.49%

Free Cashflow Yield

-0.15%

NTRA Investor Care

Shares Dilution (1Y)

9.88%

Diluted EPS (TTM)

-1.75

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2B	1.4B	1.5B	0
2023	867.8M	931.0M	988.7M	1.1B
2022	667.3M	723.5M	776.0M	820.2M
2021	449.3M	504.9M	564.8M	625.5M
2020	329.5M	341.6M	361.9M	391.0M
2019	262.1M	273.4M	286.1M	302.3M
2018	222.6M	233.4M	242.7M	257.7M
2017	204.6M	204.9M	206.9M	209.6M
2016	204.8M	211.7M	220.7M	217.1M
2015	179.4M	188.7M	187.3M	190.4M
2014	81.2M	107.2M	133.3M	159.3M
2013	0	0	0	55.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

CEO	Mr. Steven Leonard Chapman
WEBSITE	natera.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	2958

Natera Inc Frequently Asked Questions

What is the ticker symbol for Natera Inc? What does NTRA stand for in stocks?

NTRA is the stock ticker symbol of Natera Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Natera Inc (NTRA)?

As of Thu Nov 21 2024, market cap of Natera Inc is 22.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTRA stock?

You can check NTRA's fair value in chart for subscribers.

Is Natera Inc a good stock to buy?

The fair value guage provides a quick view whether NTRA is over valued or under valued. Whether Natera Inc is cheap or expensive depends on the assumptions which impact Natera Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTRA.

What is Natera Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, NTRA's PE ratio (Price to Earnings) is -104.15 and Price to Sales (PS) ratio is 14.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTRA PE ratio will change depending on the future growth rate expectations of investors.